Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
Anticancer Agents Med Chem ; 17(1): 67-74, 2017.
Artigo em Inglês | MEDLINE | ID: mdl-27141880

RESUMO

BACKGROUND: Angiogenesis is physiological process in embryogenesis, organ development, endometrial vasculature in menstrual cycle and wound healing. Angiogenesis has also been associated with several pathological conditions such as cancer, arthritis, atherosclerosis, etc. Out of the many growth factor responsible for angiogenesis, vascular endothelial growth factor (VEGF) is one of the most important and positive regulator of angiogenesis with its distinct specificity for vascular endothelial cells. The current work is the small efforts towards development of newer inhibitor of angiogenesis targeting VEGFR-2. OBJECTIVE: With the view to develop inhibitors of angiogenesis, pharmacophore characteristics were used to design aromatic/ heteroaromatic ring containing compounds. These compounds were then docked in to the active side of VEGFR-2 with the aid of docking. They were then synthesize and spectrally characterized and carry out in-vitro and in-vivo anti-angiogenic evaluation studies to ascertain its angiogenesis inhibition potential. RESULT: 3-substituted-5-(4-pyridin-4yl)-1,3,4-oxadiazole-2-thiones designed as inhibitors of angiogenesis targeting VEGFR2. In docking study, all the molecules showed similar way of binding with VEGFR2 as that of the cocrystallised ligand. Compound 3i and 3j were found to be most active in the series showing good inhibition of angiogenesis in both CAM and in zebrafish embryo assays. The compound 3i was the most active in the series with IC50 of 0.5 µM for VEGR-2. CONCLUSION: To conclude the work we have successfully designed newer inhibitors of angiogenesis targeting VEGFR- 2. These compounds were then screen and found to inhibit angiogenesis of CAM and zebrafish at dose of 1 µM.


Assuntos
Inibidores da Angiogênese/química , Inibidores da Angiogênese/farmacologia , Oxidiazóis/química , Oxidiazóis/farmacologia , Receptor 2 de Fatores de Crescimento do Endotélio Vascular/antagonistas & inibidores , Inibidores da Angiogênese/síntese química , Animais , Galinhas , Membrana Corioalantoide/irrigação sanguínea , Membrana Corioalantoide/efeitos dos fármacos , Desenho de Fármacos , Humanos , Simulação de Acoplamento Molecular , Oxidiazóis/síntese química , Tionas/síntese química , Tionas/química , Tionas/farmacologia , Receptor 2 de Fatores de Crescimento do Endotélio Vascular/metabolismo , Peixe-Zebra/embriologia
2.
Bioorg Chem ; 67: 139-47, 2016 08.
Artigo em Inglês | MEDLINE | ID: mdl-27388635

RESUMO

A series of novel 5-benzylidene-2,4-thiazolidinediones were designed as inhibitors of angiogenesis targeting VEGFR-2. In docking study, molecules showed similar way of binding with VEGFR-2 as that of the co-crystallized ligand. Compounds were then synthesized, purified and characterized by spectroscopic techniques. Compounds 3f and 3i were found to be most active in the series showing good inhibition of angiogenesis in both CAM and in zebrafish embryo assays. Compound 3i also exhibited IC50 of 0.5µM against VEGFR-2.


Assuntos
Compostos de Benzilideno/farmacologia , Desenho de Fármacos , Neovascularização Patológica/tratamento farmacológico , Inibidores de Proteínas Quinases/farmacologia , Tiazóis/farmacologia , Receptor 2 de Fatores de Crescimento do Endotélio Vascular/antagonistas & inibidores , Animais , Compostos de Benzilideno/síntese química , Compostos de Benzilideno/química , Relação Dose-Resposta a Droga , Humanos , Estrutura Molecular , Neovascularização Patológica/patologia , Inibidores de Proteínas Quinases/síntese química , Inibidores de Proteínas Quinases/química , Relação Estrutura-Atividade , Tiazóis/síntese química , Tiazóis/química , Receptor 2 de Fatores de Crescimento do Endotélio Vascular/metabolismo , Peixe-Zebra
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA